Three Doses of ZIFIVAX™ COVID 19 Vaccine Show Good Neutralising Activity Against The Delta Strain According to Inventor

Dr. Lianpan Dai, Lead Inventor & Designer of Zifivax™

Petaling Jaya, 11 August 2021 – Dr. Lianpan Dai, Lead Inventor & Designer of Zifivax™ said that according to the data recently published by the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS), the three-dose Zifivax™ vaccine showed more tolerability, good neutralising activity, and effectively fights the Delta strain.

He suggested that people get three doses of the COVID vaccine but there must be a longer interval between the second and third doses. Experiments showed almost preserved vaccine neutralising activity for all the variants.

“Zifivax™ Recombinant Protein Subunit vaccine experiment showed that four to six months after the third dose, it showed almost no decline against the Delta strain,” Dr Dai stated.

Participating with him in the live Zoom webinar on “How Effective Is Zifivax™ Vaccine Against New Variants of SARS-CoV-2 Virus”? were Guest of Honour YB Dato’ Dr. Haji Noor Azmi Bin Ghazali, Deputy Minister of Health, Ministry of Health Malaysia, and moderator Dr. Gopirajan J. Rasamy, Head of Regulatory Affairs, MYEG Medical Services Sdn. Bhd. The webinar was organised virtually on 21st July 2021.

Dr Dai added that, compared with other vaccines, Recombinant Protein Subunit contains a single protein rather than the whole virus. Recombinant protein subunit only needs a purified protein, so it is safer and has fewer side effects.

He pointed out that compared with inactive vaccines and adenovirus vaccines, recombinant protein subunit vaccines showed higher immunogenicity in experiments. Dr Dai also predicted the 3-dose regime will be widely use by other vaccines in the near future.

“Many companies like Moderna also plan to have a 3-dose regime to ensure the immunity duration. In the long run, your antibodies are not safe again, you can use the fourth dose to further enhance protection.” Dr Dai added.

“The Zifivax™ Covid vaccine R&D team conducted clinical trials, on Sinopharm and Sinovac, and used Zifivax™ as a booster; it shows better performance compared with homologous prime boost regime.”

He said that the result were not published but from the research team viewpoint, Zifivax™ is a good choice as a booster vaccine.

Zifivax™ is a new vaccine co-developed by Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. and Institute of Microbiology, Chinese Academy of Sciences. It has been granted emergency use authorisation by the China Government in early March and more than 140 million doses has been administered successfully in China.

The 3-dose Zifivax™ uses the advanced recombination technology with superior results of 97% efficacy rate in Phase 1 & Phase 2 trials. Immunisation schedule requires 3 doses instead of 2 doses as per other Recombinant Protein Subunit for disease prevention effectiveness and immune persistence. It has a good safety profile and the technology has been adopted in approved vaccines such as HPV, Hepatitis B and Herpes Zoster vaccine.

MY E.G. Services Berhad (MYEG) stated that the new corona vaccine Zifivax™ is in the final stage of approval by the National Pharmaceutical Regulatory Agency (NPRA). MYEG has inked a letter of intent with Anhui Zhifei Biopharmaceutical Co Ltd for an initial 10 million doses and will have exclusive right to the vaccine in Malaysia and Philippines.


Please enter your comment!
Please enter your name here